Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1959-1965

  Xu, Ping ^a   Qian, Xiaoning ^a   Schatz, Desmond A ^b   Cuthbertson, David ^a   Krischer, Jeffrey P ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY; AUTOANTIBODY;

ADOLESCENT; ADULT; AGE; ANTIBODY TITER; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HLA TYPING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NORTH AMERICA; ORAL GLUCOSE TOLERANCE TEST; POPULATION RISK; RISK FACTOR; SEX DIFFERENCE; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; METABOLISM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK;

ADOLESCENT; AUTOANTIBODIES; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN ANTIBODIES; MALE; NORTH AMERICA; RISK;

EID: 84903524214     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2603     Document Type: Article

References (33)

1. Rewers M, Norris J, Dabelea D. Epidemiology of diabetes. In Immunology of Type 1 Diabetes. 2nd ed. Eisenbarth GS, Ed. New York, Springer, 2004, p. 221-233
2. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-1339 (Pubitemid 14204704)
3. Eisenbarth GS, Moriyama H, Robles DT, et al. Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes. Autoimmun Rev 2002;1:139-145 (Pubitemid 38340264)
4. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984;33:486-494 (Pubitemid 14105636)
5. Shapiro ET, Tillil H, Rubenstein AH, Polonsky KS. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab 1988;67:1094-1099
6. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980;51:520-528 (Pubitemid 10022835)
7. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
8. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264 (Pubitemid 38044724)
9. Sosenko JM, Palmer JP, Rafkin LE, et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care 2010;33:620-625
10. Schatz D, Cuthbertson D, Atkinson M, et al. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression? Pediatr Diabetes 2004;5:72-79 (Pubitemid 38923633)
11. Verge CF, Howard NJ, Irwig L, Simpson JM, Mackerras D, Silink M. Environmental factors in childhood IDDM. A population-based, case-control study. Diabetes Care 1994;17:1381-1389 (Pubitemid 24980231)
12. Akerblom HK, Vaarala O, Hyöty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002;115:18-29 (Pubitemid 34657185)
13. van der Werf N, Kroese FGM, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007;23:169-183 (Pubitemid 46437842)
14. Diabetes Prevention Trial -Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
15. Sosenko JM, Krischer JP, Palmer JP, et al.; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 2008;31:528-533
16. Smirnov NV. Tables for estimating the goodness of fit of empirical distributions. Ann Math Stat 1948;19:279
17. Koenker R, Hallock K. Quantile regression: an introduction. J Econ Perspect 2001;15:143-156
18. Hao L, Naiman DQ. Quantile Regression. Thousand Oaks, CA, Sage Publications, 2007
19. SAS Institute Inc. The QUANTREG Documentation. In SAS/STAT 9.2 User's Guide. Cary, NC, SAS Institute Inc., 2008
20. Krarup T, Regeur L, Faber OK, Binder C. Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol (Copenh) 1980;95:359-363 (Pubitemid 11211731)
21. Lee PA, Guo SS, Kulin HE. Age of puberty: data from the United States of America. APMIS 2001;109:81-88 (Pubitemid 32424134)
22. Herman-Giddens ME, Wang L, Koch G. Secondary sexual characteristics in boys: estimates from the national health and nutrition examination survey III, 1988-1994. Arch Pediatr Adolesc Med 2001;155:1022-1028 (Pubitemid 32824047)
23. Anderson SE, Dallal GE, Must A. Relative weight and race influence average age at menarche: results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics 2003;111:844-850 (Pubitemid 36402912)
24. Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP; DPT-1 Study Group. Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 2012;35:1975-1980
25. Xu P, Wu Y, Zhu Y, et al.; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care 2010;33:2508-2513
26. Sosenko JM, Palmer JP, Greenbaum CJ, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649 (Pubitemid 44115367)
27. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
28. Jaeger C, Allendörfer J, Hatziagelaki E, et al. Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual betacell function, neuropathy or HLA-DR status. Horm Metab Res 1997;29:510-515 (Pubitemid 27496348)
29. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012;35:465-470
30. Nicole AS, Emily BT, Kevan CH. Natural history of β-cell function in type 1 diabetes. Diabetes 2005;54(Suppl. 2):S32-S39
31. Thunander M, Törn C, Petersson C, Ossiansson B, Fornander J, Landin-Olsson M. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol 2012;166:1021-1029
32. Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group. Male sex increases the risk of autoimmunity but not type 1 diabetes. Diabetes Care 2004;27:1985-1990 (Pubitemid 38989243)
33. Weets I, Truyen I, Verschraegen I, et al.; Belgian Diabetes Registry. Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia 2006;49:1158-1162